



Sequoia provides ongoing posting on LinkedIn of articles of interest that affect our market space. Please connect and follow our Sequoia LinkedIn page to learn more and obtain ongoing updates on specialty pharmacy and other important topics impacting risk.

<https://www.linkedin.com/company/sequoia-reinsurance-services-llc>

The Institute for Clinical and Economic Review (ICER), in a joint effort with the Office of Health Economics (OHE), has discharged another white paper: "Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates." The 33-page paper illustrates the potential focal points and impediments of three options drives pharmaceutical value arrangement in the US.

The white paper was created following a December 2018 gathering of ICER's participation program, amid which pioneers from the pharmaceutical and insurance industries met to share their points of view on how rebates became progressively imperative for their organizations, the unintended results they have had on drug affordability for specific patients, and conceivable ways forward.

Please enjoy the article linked below and contact Jakki Lynch, Director of Cost Containment directly at (415) 360-5197 or by email [jlynch@sequoiaris.com](mailto:jlynch@sequoiaris.com) to discuss our specialty pharmacy cost management strategies.

<https://icer-review.org/wp-content/uploads/2019/03/March-2019-ICER-OHE-White-Paper-on-Rebates-Final.pdf>

---